ENTX insider trading
HealthcareEntera Bio Ltd.: insider trade history from SEC Form 4 filings.
About Entera Bio Ltd.
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.
Company website: www.enterabio.com
ENTX insider activity at a glance
FilingIQ tracks 76 insider transactions for ENTX in filings since Jan 18, 2022. The most recent transaction is dated Aug 7, 2026.
Across the full history, 37 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ENTX insider trades is 63.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ENTX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading ENTX
Frequently asked
- How many insider trades does FilingIQ track for ENTX?
- FilingIQ tracks 76 Form 4 insider transactions for ENTX (Entera Bio Ltd.), covering filings from Jan 18, 2022 onwards. 6 of those are dated within the last 90 days.
- Are ENTX insiders net buyers or net sellers?
- Across the full Form 4 history for ENTX, 37 transactions (49%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ENTX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ENTX in?
- Entera Bio Ltd. (ENTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $64.66M.
Methodology & sources
Every ENTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.